ACIU trades 194.3% below Wall Street's consensus target of $8.33.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ACIU achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, AC Immune S.A. (ACIU) has a Wall Street consensus price target of $8.33, based on estimates from 9 covering analysts. With the stock currently trading at $2.83, this represents a potential upside of +194.3%. The company has a market capitalization of $288M.
Analyst price targets range from a low of $7.00 to a high of $10.00, representing a 36% spread in expectations. The median target of $8.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ACIU trades at a trailing P/E of -3.3x. Analysts expect EPS to grow +6.4% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $0.06, with bear and bull scenarios of $0.04 and $0.07 respectively. Model confidence stands at 49/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 PRAXPraxis Precision Medicines, Inc. | $7.9B | $282.12 | $603.83 | +114.0% | Buy | — | 18 |
 SAVACassava Sciences, Inc. | $45M | $0.94 | — | — | Buy | — | 12 |
 ANVSAnnovis Bio, Inc. | $54M | $1.27 | — | — | — | — | — |
 NRXPNRx Pharmaceuticals, Inc. | $55M | $3.16 | — | — | — | — | — |
 BIIBBiogen Inc. | $33.6B | $227.53 | $245.88 | +8.1% | Buy | 18.3x | 49 |
 LLYEli Lilly and Company | $1.1T | $1152.70 | $1343.07 | +16.5% | Buy | 31.7x | 45 |
 IONSIonis Pharmaceuticals, Inc. | $7.3B | $43.93 | $86.25 | +96.3% | Buy | — | 33 |
 PRTAProthena Corporation plc | $454M | $8.68 | $30.00 | +245.6% | Buy | 78.9x | 28 |
 ALNYAlnylam Pharmaceuticals, Inc. | $32.9B | $246.51 | $347.33 | +40.9% | Buy | 36.9x | 52 |
 RCUSArcus Biosciences, Inc. | $3.3B | $26.39 | $40.00 | +51.6% | Buy | — | 18 |
Quick answers to the most common questions about buying ACIU stock.
The consensus Wall Street price target for ACIU is $8.33, representing 194.3% upside from the current price of $2.83. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
ACIU has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 8 Buy/Strong Buy ratings. The consensus 12-month price target of $8.33 implies 194.3% upside from current levels.
ACIU's current price is $2.83 with a consensus target of $8.33 (194.3% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $10 for ACIU, while the most conservative target is $7. The consensus of $8.33 represents the median expectation. Our quantitative valuation model projects a bull case target of $0 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
ACIU is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ACIU stock forecast based on 9 Wall Street analysts shows a consensus price target of $8.33, with estimates ranging from $7 (bear case) to $10 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $0, with bear/bull scenarios of $0/$0.
Our quantitative valuation model calculates ACIU's fair value at $0 (base case), with a bear case of $0 and bull case of $0. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 49/100.
Wall Street analysts are very optimistic on ACIU, with a "Buy" consensus rating and $8.33 price target (194.3% upside). 8 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ACIU analyst price targets range from $7 to $10, a 36% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $8.33 consensus represents the middle ground. Our model's $0-$0 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.